
In a report released today, Robert Burns from H.C. Wainwright maintained a Buy rating on PMV Pharmaceuticals, with a price target of $5.00. Robert Burns’s Buy rating is based on
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | 0.88 | 0.00 | 0.00% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.88 | 0.00% |

In a report released today, Robert Burns from H.C. Wainwright maintained a Buy rating on PMV Pharmaceuticals, with a price target of $5.00. Robert Burns’s Buy rating is based on

PMV Pharmaceuticals (PMVP) reported updated results from the pivotal Phase 2 portion of the PYNNACLE clinical trial of rezatapopt monotherapy in patients with TP53 Y220C-mutated advanced solid tumors. The data

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on PMV Pharmaceuticals, with a price target of $5.00. Robert Burns has given his Buy rating

“We achieved significant milestones during the third quarter across the organization,” said David Mack, President and Chief Executive Officer of PMV Pharma. “The updated monotherapy interim data demonstrate the potential

PMV Pharmaceuticals ( ($PMVP) ) has issued an update. On October 1, 2026, PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a veteran healthcare investor and scientist, to its board of directors

PMV Pharmaceuticals (PMVP) announced the appointment of Philip Herman as chief commercial officer, or CCO. Herman will lead the company’s commercial strategy and launch preparation for rezatapopt, PMV Pharma’s p53

PMV Pharmaceuticals ( ($PMVP) ) just unveiled an announcement. On August 31, 2026, PMV Pharmaceuticals priced an oversubscribed underwritten public offering of common stock, pre-funded warrants and accompanying warrants to

TD Cowen is acting as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’

An announcement from PMV Pharmaceuticals ( ($PMVP) ) is now available. On August 31, 2026, PMV Pharmaceuticals reported updated interim data from the ovarian cancer cohort of its PYNNACLE Phase

PMV Pharmaceuticals (PMVP) announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational Phase 2 trial is assessing rezatapopt
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 3, 2027TBA | $98.95M | $-0.27 | $0.00 | -0.03 | -0.85 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.